Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
08 Sep 2023
Historique:
accepted: 16 08 2023
received: 08 03 2023
revised: 15 08 2023
medline: 8 9 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: aheadofprint

Résumé

An early event in the genesis of follicular lymphoma (FL) is the acquisition of new glycosylation motifs in the B cell receptor (BCR) due to gene rearrangement and/or somatic hypermutation. These N-linked glycosylation motifs (N-motifs) contain mannose-terminated glycans and can interact with lectins in the tumor microenvironment, activating the tumor BCR pathway. N-motifs are stable during FL evolution suggesting that FL tumor cells are dependent on them for their survival. Here, we investigated the dynamics and potential impact of N-motif prevalence in FL at the single cell level across distinct tumor sites and over time in 17 patients. While most patients had acquired at least one N-motif as an early event, we also found (i) cases without N-motifs in the heavy or light chains at any tumor site or timepoint and (ii) cases with discordant N-motif patterns across different tumor sites. Inferring phylogenetic trees for the patients with discordant patterns, we observed that both N-motif-positive and N-motif-negative tumor subclones could be selected and expanded during tumor evolution. Comparing N-motif-positive to N-motif-negative tumor cells within a patient revealed higher expression of genes involved in the BCR pathway and inflammatory response, while tumor cells without N-motifs had higher activity of pathways involved in energy metabolism. In conclusion, while acquired N-motifs likely support FL pathogenesis through antigen-independent BCR signaling in most FL patients, N-motif-negative tumor cells can also be selected and expanded and may depend more heavily on altered metabolism for competitive survival.

Identifiants

pubmed: 37683139
pii: 497825
doi: 10.1182/blood.2023020360
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : K08 CA252637
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197353
Pays : United States

Informations de copyright

Copyright © 2023 American Society of Hematology.

Auteurs

Sarah Elena Haebe (SE)

Stanford University, Stanford, California, United States.

Grady Day (G)

Stanford University, Stanford, California, United States.

Debra K Czerwinski (DK)

Stanford University Medical Center, Stanford, California, United States.

Anuja Sathe (A)

Stanford University, Stanford, California, United States.

Susan M Grimes (SM)

Stanford University, Palo Alto, California, United States.

Tianqi Chen (T)

Stanford University, Stanford, California, United States.

Steven R Long (SR)

UCSF, San Francisco, CA, California, United States.

Brock A Martin (BA)

Stanford University School of Medicine, United States.

Michael G Ozawa (MG)

Stanford University Medical Center, Stanford, California, United States.

Hanlee P Ji (HP)

Stanford University, Stanford, California, United States.

Tanaya Shree (T)

Stanford University School of Medicine, United States.

Ronald Levy (R)

Stanford University Medical Center, Stanford, California, United States.

Classifications MeSH